Skip to content

A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients

A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033049
Enrollment
Unknown
Registered
2020-05-18
Start date
2020-05-19
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:Taking artemisinin-pipequine tablets

Sponsors

Hongqi Hospital Affiliated to Mudangjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old, and signed informed consent; 2. According to the diagnostic criteria of the ''New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7)'' issued by the National Health and Health Commission, those who have been diagnosed with CoVID-19 of light and common type. The specific diagnostic criteria are as follows: (1) light type: The clinical symptoms are mild, and there is no pneumonia manifestation in imaging; (2) Common type: It has fever, respiratory tract and other symptoms. Pneumonia can be seen on imaging.

Exclusion criteria

Exclusion criteria: 1. Female patients in pregnancy; 2. Identify patients who are allergic to 4-aminoquinoline compounds. 3. Patients with diseases of the blood system. 4. Patients with liver and kidney disease or those with liver and kidney injury. 5. Patients with arrhythmia and chronic heart disease. 6. Patients with known retinal diseases, hearing loss or hearing loss. 7. Patients with known mental illness. 8. Skin diseases (including rash, dermatitis, psoriasis). 9. Due to the original underlying diseases, digitalis drugs, sparfloxacin, levofloxacin, moxifloxacin, streptomycin, penicillamine, clarithromycin, amiodarone, apomorphine, hydrochlorothiazide, boraxone Heparin, benpredil, domperidone, droperidol, haloperidol, astemizole, erythromycin, posaconazole, methadone, procainamide, cisapride, indapamide, chlorpromazine Patients with azine, ammonium chloride, ondansetron, octreotide monoamine oxidase inhibitors, fluoxyprednisolone.

Design outcomes

Primary

MeasureTime frame
Viral load of nCoV;Blood test;Immunological examination;Blood liver and kidney function test;Myocardial enzyme biochemical examination;ECG examination;Routine urine test;body temperature;pulse;Breathe;blood pressure;CT examination of the lungs;

Countries

China

Contacts

Public ContactFengjie Xie

Hongqi Hospital Affiliated to Mudanjiang Medical College

mdjxfj1971@126.com+86 13514563699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026